Aducanumab and the FDA — where are we now?

Fillit, Howard; Green, Allan

doi:10.1038/s41582-020-00454-9

Record: found
Abstract: not found
Article: not found

Aducanumab and the FDA — where are we now?

Author(s): Howard Fillit , Allan Green

Publication date (Electronic): January 13 2021

Journal: Nature Reviews Neurology

Publisher: Springer Science and Business Media LLC

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Contributors

Howard Fillit: (View ORCID Profile)

Journal

Title: Nature Reviews Neurology

Abbreviated Title: Nat Rev Neurol

Publisher: Springer Science and Business Media LLC

ISSN (Print): 1759-4758

ISSN (Electronic): 1759-4766

Publication date (Electronic): January 13 2021

Article

DOI: 10.1038/s41582-020-00454-9

PubMed ID: 33442064

SO-VID: 658b0425-ea51-4eaa-a824-ebf017497e73

License:

http://www.springer.com/tdm

History

Data availability:

Aducanumab and the FDA — where are we now?

Read this article at

Related collections

ScienceOpen Research

Author and article information

Contributors

Journal

Article

History

Comments

Comment on this article

Similar content 911

Cited by 27